Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer

被引:179
作者
House, Michael G.
Goenen, Mithat
Jarnagin, William R.
D'Angelica, Michael
DeMatteo, Ronald P.
Fong, Yuman
Brennan, Murray F.
Allen, Peter J.
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Surg & Epidemiol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
关键词
pancreas; adenocarcinoma; lymph nodes; survival;
D O I
10.1007/s11605-007-0243-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The purpose of this study was to evaluate the significance of pathologic nodal assessment and extent of nodal metastases on patient outcome in patients with pancreatic adenocarcinoma. Materials and Methods A prospectively maintained pancreatic cancer database was reviewed, and 696 consecutive patients were identified who underwent resection for pancreatic adenocarcinoma between 1995 and 2005. Overall survival was compared to lymph node (LN) status, absolute number of pathologically assessed LN, and LN ratio expressed as the number of positive LN to the total LN assessed. Results Of the 696 patients, 598 (86%) had pancreaticoduodenectomy (PD), and 96 (14%) had distal pancreatectomy (DP). For all patients, median follow-up was 13 months (range, 0-122 months), and estimated 5-year survival was 16%. A total of 243 (35%) patients were LN-negative (N0) and had a median survival of 27 months. When assessed as a continuous variable, the number of pathologically assessed LN did not correlate with survival for N0 patients undergoing either PD or DP. The median survival for the 453 patients with node-positive (N1) disease was 16 months. When analyzed as a continuous variable, the absolute number of positive LNs was a significant predictor of survival for N1 patients with a linear relationship up to eight positive LNs. LN ratio, as a continuous variable, also predicted survival with a linear relationship up to a ratio of 0.35. A ratio of 0.18 was associated with a 19-month median survival and served as the best cutoff, p < 0.01. Conclusions The absolute number of positive LNs and LN ratio are strong predictors of survival for patients with node-positive pancreatic adenocarcinoma. Inadequate surgical lymphadenectomy or pathologic LN assessment understages node-negative patients.
引用
收藏
页码:1549 / 1555
页数:7
相关论文
共 28 条
[1]  
*AJCC, 2002, AJCC CANC STAG MAN
[2]   Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): Impact of adequate staging on outcome [J].
Barbour, Andrew P. ;
Rizk, Nabil P. ;
Gonen, Mithat ;
Tang, Laura ;
Bains, Manjit S. ;
Rusch, Valerie W. ;
Coit, Daniel G. ;
Brennan, Murray F. .
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) :306-316
[3]   Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes [J].
Berger, AC ;
Sigurdson, ER ;
LeVoyer, T ;
Hanlon, A ;
Mayer, RJ ;
Macdonald, JS ;
Catalano, PJ ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8706-8712
[4]  
Berger AC, 2004, AM SURGEON, V70, P235
[5]   Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas [J].
Brennan, MF ;
Kattan, MW ;
Klimstra, D ;
Conlon, K .
ANNALS OF SURGERY, 2004, 240 (02) :293-298
[6]   LONG-TERM SURVIVAL FOLLOWING PANCREATICODUODENECTOMY FOR ADENOCARCINOMA OF THE HEAD OF THE PANCREAS [J].
CAMERON, JL .
SURGICAL CLINICS OF NORTH AMERICA, 1995, 75 (05) :939-&
[7]   Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors [J].
Cleary, SP ;
Gryfe, R ;
Guindi, M ;
Greig, P ;
Smith, L ;
Mackenzie, R ;
Strasberg, S ;
Hanna, S ;
Taylor, B ;
Langer, B ;
Gallinger, S .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 198 (05) :722-731
[8]   Long-term survival after curative resection for pancreatic ductal adenocarcinoma - Clinicopathologic analysis of 5-year survivors [J].
Conlon, KC ;
Klimstra, DS ;
Brennan, MF .
ANNALS OF SURGERY, 1996, 223 (03) :273-279
[9]   AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma [J].
DiMagno, EP ;
Reber, HA ;
Tempero, MA .
GASTROENTEROLOGY, 1999, 117 (06) :1464-1484
[10]  
Gazzaniga GM, 2001, HEPATO-GASTROENTEROL, V48, P1471